Obesity has become a major worldwide challenge to public health, due to the Western 'obesogenic' environment interacting with a strong genetic contribution[@R1]. Recent extensive genome-wide association studies (GWAS) have identified numerous single nucleotide polymorphisms (SNPs) associated with obesity, but these loci together account for only a small fraction of the known heritable component[@R1]. Thus, the "common disease, common variant" paradigm is increasingly under challenge[@R2]. We report a highly-penetrant form of obesity, initially observed in 31 subjects who were heterozygous for deletions of at least 593kb at 16p11.2 and whose ascertainment included cognitive deficits. Nineteen similar deletions were identified from GWAS data in 16053 individuals from 8 European cohorts. Such deletions were absent from healthy non-obese controls and accounted for 0.7% of our morbid obesity cases (body mass index, BMI ≥ 40 kg.m^−2^ or BMI standard deviation score ≥ 4; p = 6.4×10^−8^, OR = 43.0), demonstrating the potential importance in common disease of rare variants with strong effects. This highlights a promising strategy for identifying missing heritability in obesity and other complex traits: Cohorts with extreme phenotypes are likely to be enriched for rare variants, thereby improving power for their discovery. Subsequent analysis of the loci so identified may well reveal additional rare variants that further contribute to the missing heritability, as recently reported for *SIM1[@R3]*. Thus, the most productive approach may be to combine the "power of the extreme"[@R4] in small, well-phenotyped cohorts, with targeted follow-up in GWAS and population cohorts.

The extent to which copy number variants (CNVs) might contribute to the missing heritability of common disorders is currently much under debate[@R2]. Since the majority of common simple CNVs are well-tagged by SNPs, it has recently been suggested that common CNVs are unlikely to contribute substantially to the missing heritability[@R5]. However, rare variants or recurring CNVs that have arisen on multiple independent occasions are unlikely to be captured by SNP tagging, and their identification will require alternative approaches.

We have previously hypothesised that cohorts with extreme phenotypes that include obesity may be enriched for rare but very potent risk variants[@R4],[@R6]. Here we have investigated 312 subjects, from three centres in the UK and France, presenting with congenital malformations and/or developmental delay in addition to obesity as previously defined[@R6],[@R7] (see Methods). Known syndromes (e.g. Prader-Willi, fragile X etc.) were excluded. A combination of array comparative genomic hybridisation (aCGH), genotyping arrays, quantitative PCR (qPCR) and multiplex ligation-dependent probe amplification (MLPA) was used to identify and confirm the presence of a heterozygous deletion on 16p11.2 in 9 individuals (2.9%). Such deletions, estimated to be a total of 740kb in size (one copy of a segmental duplication plus 593kb of unique sequences, [Figure 1a](#F1){ref-type="fig"}), have previously been associated to varying extents with autism, schizophrenia and developmental delay[@R8]-[@R11]; however, the observed frequency of deletions in our cohort is appreciably higher than the reported frequencies in the cohorts from the previous studies (\<1%), which did not include obesity as an inclusion criterion.

A parallel, independent survey of aCGH and SNP-CGH data from 8 cytogenetic centres in France, Switzerland and Estonia, of 3,947 patients with developmental delay and/or malformations, but this time without selection for obesity, revealed 22 unrelated cases with similar deletions (0.6%). This is a frequency consistent with the previous studies[@R8]-[@R11], but is significantly lower than for the above cohort which included only obese subjects (p=2.2×10^−4^, Fisher's exact test).

Analysis of the available clinical data for these 22 new carriers indicated that, in addition to the ascertained cognitive deficits or behavioural abnormalities (including hyperphagia, specifically identified in at least 9 cases; see [Supplementary Table S1](#SD2){ref-type="supplementary-material"}), a 16p11.2 deletion gave rise to a strongly-expressed obesity phenotype in adults, with a more variable phenotype in childhood. All 4 teenagers and adults carrying a deletion were obese, while child carriers were also frequently either obese (4/15) or overweight (2/15), a tendency that has previously been noted[@R11]; the very young (under 2 years) were of normal weight. This age-dependent penetrance was observed for all instances of deletions where phenotypic data were available, whether from this study or from previously published reports[@R10]-[@R15], and regardless of ascertainment ([Figure 2](#F2){ref-type="fig"}; see Supplementary Tables [S2](#SD2){ref-type="supplementary-material"} and [S3](#SD2){ref-type="supplementary-material"}).

Taken together, the data from these parallel studies suggest a possible direct association of deletions at 16p11.2 with obesity, distinct from their cognitive phenotype. Also identified in these cohorts were instances of the reciprocal duplication, which has also been implicated in neurodevelopmental disorders, but with a variable phenotype and lower penetrance[@R9],[@R10],[@R12]. The frequency of the duplication in the two cohorts (12/4183, 0.3%) was consistent with previous reports for patients with cognitive deficits (0.3--0.7%)[@R10],[@R12]. Carriers of the duplication were neither obese nor had reported hyperphagia.

To further investigate the association of 16p11.2 deletions with obesity, and to estimate the extent to which it is observed independently of ascertainment for neurodevelopmental symptoms, we carried out algorithmic and statistical analyses of genome-wide SNP genotyping data (see [Table 1](#T1){ref-type="table"}) from Swiss (CoLaus^[@R16]^), Finnish (NFBC66^[@R17]^) and Estonian (EGPUT^[@R18]^) general population cohorts (11,856 subjects in total), from child obesity and adult morbid obesity case-control cohorts^[@R6],[@R19],[@R20]^ (1,224 and 1,548 subjects respectively), from an extreme early-onset obesity cohort (SCOOP, 931 subjects) and from 141 patients undergoing bariatric weight-loss surgery (see online Methods); in total, we identified 17 instances of deletions (and 4 duplications) with no significant gender bias ([Table 1](#T1){ref-type="table"}). In addition, we identified 2 further unrelated carriers of a deletion from amongst 353 members of 149 families with sibling pairs discordant for obesity (SOS Sib Pair Study[@R21]). Where DNA was available for further analysis (15/19 samples), the presence of a deletion was validated using MLPA ([Figure 1b](#F1){ref-type="fig"}) or qPCR; the remaining deletions were validated by applying a second independent algorithm to the data. With the exception of a single individual who is apparently diabetic (fasting glucose \> 7 mmol/L), all adult carriers of such deletions were obese, the majority being morbidly obese; similarly, each of the 7 child/adolescent carriers had a BMI in the top 0.1% of the population range for their age and gender. None of the individuals ascertained on the basis of their obesity had any reported developmental delay or cognitive deficit; four subjects were reported as having hyperphagia.

To enable sufficient statistical power to give robust conclusions, we combined data from the population and obesity cohorts in an overall case-control association analysis (the samples from sib pair families were excluded to avoid complications due to their relatedness). Compared to lean/normal weight subjects (see [Table 1](#T1){ref-type="table"} and Methods), 16p11.2 deletions were associated with obesity (p = 5.7×10^−7^, Fisher's exact test; odds ratio = 29.8, 95% confidence limits = 4.0, 225) and morbid obesity (p = 6.4×10^−8^; OR = 43.0 \[5.6, 329\]) at or near genome-wide levels of significance. Expanding the control group to include all non-obese individuals increased the significance to p = 4.1×10^−9^ (obese) and p = 6.1×10^−10^ (morbidly obese).

Previous reports have indicated that these deletions are frequently not inherited from either parent but arises *de novo*, possibly by non-allelic homologous recombination between the \>99% sequence identical segmental duplications flanking the deleted region[@R11],[@R14]. Therefore, where possible we investigated the parents of carriers of deletions, identifying 11 cases of maternal transmission and 4 of paternal transmission. The available data showed that all first-degree relatives carrying a deletion were also obese ([Supplementary Table S1](#SD2){ref-type="supplementary-material"}). In 10 instances the deletion was apparently *de novo* (see [Figure 1b](#F1){ref-type="fig"}). Extrapolation to our full dataset indicates that \~0.4% of all morbidly obese cases are due to an inherited 16p11.2 deletion. The frequency of *de novo* events is consistent with the previous report where ascertainment was for developmental delay and/or congenital anomalies[@R11]; by contrast, deletions are reported to be almost exclusively *de novo* in autistic subjects[@R8]-[@R10].

Although they may be heterogeneous in nature, these deletions are highly likely to be the causal variants, representing the second most frequent genetic cause of obesity after point mutations in *MC4R*[@R22],[@R23]. Their repeated *de novo* occurrence is likely to result in lack of linkage disequilibrium with any other flanking variant -- no consistent haplotype has been identified by analysis of the available surrounding genotypes. To assess the effect of a deletion on the expression of nearby genes (e.g. the obesity GWAS-associated *SH2B1* locus 800kb away[@R24]), we analysed available transcript data for subcutaneous adipose tissue samples from the discordant sibling cohort. Comparisons of the 2 subjects carrying a deletion with their corresponding non-obese siblings, and with other obese and non-obese subjects ([Supplementary Figure S4](#SD2){ref-type="supplementary-material"} and Supplementary Tables [S4](#SD2){ref-type="supplementary-material"} and [S5](#SD2){ref-type="supplementary-material"}), showed that many though not all transcripts from within the deletion had markedly reduced abundance (0.4-0.7 fold). In contrast, no clear evidence was found for consistent *cis* effects of the deletion on the abundance of mRNAs encoded by genes flanking the deletion. In addition, global analysis of this dataset has not identified any *trans* expression quantitative trait loci either within or nearby the deletion.

Thus, while we cannot completely exclude that a 16p11.2 deletion affects the expression of nearby genes (for instance, its impact may be different in other tissues), the above expression analysis strongly indicates that the observed phenotypes are likely to be due to haploinsufficiency of one or more of the \~30 genes within the deleted region. Indeed, rather than being due to a single haploinsufficiency, the phenotype may well result from the deletion of multiple genes that impact on pathways central to the development of obesity (see [Supplementary Table S5](#SD2){ref-type="supplementary-material"}). Functional network analysis of the deleted genes has led to the suggestion of a similar multi-gene effect for the cognitive phenotype[@R8]. The extent to which there is overlap between the genes involved in the obesity and cognitive phenotypes remains to be elucidated.

There is a strong correlation between developmental and cognitive disabilities and the prevalence of obesity: Patients with autism or who have learning disabilities have a greatly increased risk of obesity[@R25]; and the severely obese exhibit significant cognitive impairment[@R26]. Possible explanations include a direct causal relationship between obesity and developmental delay; the involvement of the same or related regulatory pathways; or different outcomes of the same set of behavioural disorders with complex pleiotropic effects and variable ages of onset and expressivities. The higher frequency of 16p11.2 deletions in the cohort ascertained for both phenotypes (2.9%), compared to cohorts ascertained for either phenotype alone (0.4%, 0.6% respectively), confirms their impact on both obesity and developmental delay, adding to the evidence that these two phenotypes may be fundamentally interrelated.

Methods Summary {#S1}
===============

Obesity {#S2}
-------

Definitions for overweight, obesity and morbid obesity were based on previous studies[@R6],[@R7]: for adults, BMI ≥ 25, 30 and 40 kg.m^−2^ respectively; for children, BMI respectively above the 90^th^, 97^th^ percentiles and ≥ 4 standard deviations above the mean, calculated according to their age and gender from a French reference population[@R27],[@R28].

Statistics {#S3}
----------

All reported statistical tests used Fisher's exact test[@R29], carried out on contingency tables constructed for the number of subjects carrying/lacking a 16p11.2 deletion versus the obesity status/ascertainment of the individual. Since no homozygous deletions were observed, it was unnecessary to make a prior distinction between recessive, additive and dominant models of disease risk. Odds ratios and 95% confidence limits were calculated as described[@R30].

CNV discovery {#S4}
-------------

Subjects ascertained for cognitive deficit/malformations with or without obesity were selected from those clinically referred for genetic testing; 16p11.2 deletions were identified in these individuals by standard clinical diagnostic procedures. Algorithmic analyses of GWAS data were variously carried out using the cnvHap algorithm; a moving window average intensity procedure; a Gaussian Mixture Model; QuantiSNP; PennCNV; BeadStudio GT module; and Birdseed. Where experimental validation was not possible, at least two independent algorithms were used for each dataset.

Online Methods {#S5}
==============

Obesity phenotype {#S6}
-----------------

We have used previously-defined criteria for to define overweight, obesity and morbid (class III) obesity[@R6],[@R7]; in adults, the thresholds were BMI ≥ 25, 30 and 40 kg.m^−2^ respectively. In children and adolescents, we used age- and sex-specific percentiles of BMI, calculated from a French reference population[@R27],[@R28], that approximately correspond to these thresholds: overweight and obesity were defined by thresholds at the 90^th^ and 97^th^ percentiles respectively. Childhood morbid obesity was defined as BMI ≥ 4 SDs above the age- and sex-specific mean, which corresponds to a BMI of 40 kg.m^−2^ between the ages of 20 and 30 years for both men and women; this threshold was used in the recruitment of the SCOOP severe early-onset obesity cohorts[@R7]. The age- and sex-specific thresholds use to define obesity and morbid obesity are shown in [Figure 1](#F1){ref-type="fig"} and Supplementary Figures [1](#SD2){ref-type="supplementary-material"}-[2](#SD2){ref-type="supplementary-material"}. No carriers of a 16p11.2 deletion were reported to be taking atypical antipsychotics (known to be associated with weight gain).

Patient and population cohorts {#S7}
------------------------------

### Patients referred for cognitive delay and obesity {#S8}

A group of 33 patients was selected from those referred for genetic testing at the North West Thames Regional Genetics Service, based at Northwick Park Hospital in Harrow, UK, with approval from the Harrow Research Ethics Committee. Inclusion was based on 3 criteria: mental retardation; dysmorphology; and weight \>97^th^ percentile for age and gender. Abnormal karyotype, Fragile X and Prader Willi Syndrome were previously excluded.

A second group of 279 French children were selected from those referred to 2 centres (Laboratoire de Diagnostic Génétique, Nouvel Hôpital Civil, Strasbourg; Centre de Génétique Chromosomique, Hôpital Saint-Vincent de Paul, GHICL, Lille). Inclusion was based on obesity plus at least one Prader Willi-like syndromic feature (neonatal hypotonia and difficulty to thrive, mental retardation, developmental delay, behavioural problems, skin picking, facial dysmorphism, hypogenitalism or hypogonadism). Chromosomal abnormalities and Prader Willi Syndrome were excluded by karyotyping and DNA methylation analysis.

### Patients referred for cognitive delay {#S9}

Patients with cognitive deficits are routinely referred to clinical genetics for etiological work-ups including aCGH. We surveyed 7 cytogenetic centres in France and Switzerland, identifying 3870 patients ascertained for developmental delay and/or malformations. Also included in the study were a further 77 patients, ascertained on similar criteria, who were referred to the Department of Genetics, University of Tartu. These analyses were performed for clinical diagnostic purposes, all available phenotypic data (weight, height) being those provided anonymously by the clinician ordering the analysis. Consequently, research-based informed consent was not required by the institutional review board that approved the study.

### CoLaus {#S10}

This prospective population cohort was described previously[@R16]: 6188 white individuals aged 35--75 years were randomly selected from the general population in Lausanne, Switzerland. These individuals underwent a detailed phenotypic assessment, and were genotyped using the Affymetrix Mapping 500K array; 5612 samples passed genotyping quality control. This study was approved by the institutional review boards of the University of Lausanne, and written consent was obtained from all participants. Because recruitment of this cohort required the ability to give informed consent, it is possible that the (statistically non-significant) lack of 16p11.2 deletions/duplications is due to an ascertainment bias. However, any such bias, if it exists, is very small and affects the identification of only 1-2 subjects carrying a deletion.

### NFBC1966 {#S11}

*The Northern Finland Birth Cohort 1966* is a prospective birth cohort of almost all individuals born in 1966 in the two northernmost provinces of Finland. Expectant mothers were enrolled and clinical data collection took place prenatally, at birth, and at ages six months, one year, 14 years and 31 years. Biochemical and DNA samples were collected with informed consent at age 31 years. Genotyping using the Illumina Infinium 370cnvDuo array and phenotypic characteristics of the cohort were as previously described[@R17]. Phenotypic and genotyping data was available for 5246 subjects after quality control.

### EGPUT {#S12}

The Estonian Genome Project is a biobank coordinated by the University of Tartu (EGPUT)[@R18]. The project is conducted according to Estonian Gene Research Act and all participants have given written informed consent. The cohort includes more than 39000 individuals older than 18 years of age and reflects closely the age distribution in the Estonian population (33% male, 67% female; 83% Estonians, 14% Russians, 3% other). Subjects are recruited by general practitioners (GP) and hospital physicians and are then randomly selected. Computer Assisted Personal interview (CAPI) was filled during 1-2 hours at the doctor's office. The data included personal data (place of birth, place(s) of living, nationality etc.), family history (four generations), educational and occupational history, lifestyle and anthropometric data. 1090 randomly-selected subjects were genotyped using the Illumina 370cnvDuo array, 998 passing the required criteria (nationality, genotyping call rate, phenotype availability).

### Case-Control familial obesity {#S13}

The adult-obesity case-control groups and the child-obesity case control groups were as previously published[@R6], and were genotyped using the Illumina Human CNV370-duo array. 643 children with familial obesity (BMI ≥ 97^th^ percentile corrected for gender and age, at least one obese first degree relative, age \< 18 yr), 581 non-obese children (BMI ≤ 90^th^ percentile), 705 morbidly obese adults with familial obesity (BMI ≥ 40 kg/m^2^, at least one obese first degree relative with BMI ≥ 35 kg/m^2^, age ≥ 18 yr) and 197 lean adults (BMI ≤ 25 kg/m^2^) passed quality control; this cohort included a further 646 control subjects from the DESIR prospective cohort[@R19] (age at exam ≥ 45 yr, normal fasting glucose according to 1997 ADA criteria, BMI \< 27 kg/m^2^) genotyped using the Illumina Hap300 array[@R20]. All participants or their legal guardians gave written informed consent, and all local ethics committees approved the study protocol.

### Severe early-onset obesity cohort {#S14}

The Genetics of Obesity Study (GOOS) cohort consists of over 3000 patients ascertained for severe obesity, defined as a BMI ≥ 4 SDs above the age- and sex-specific mean, and onset of obesity before 10 years of age. In this study, we selected a discovery set of 1000 UK Caucasian patients from this cohort in whom developmental delay had been excluded by routine clinical examination by experienced Physicians (this cohort is referred to as SCOOP). Mutations in *LEPR, POMC* and *MC4R* were excluded by direct nucleotide sequencing and a karyotype was performed. DNA samples were analysed using Affymetrix Genome-Wide Human SNP Array 6.0 by Aros, Inc (Århus, Denmark), of which 931 passed quality control.

### Bariatric surgery cohort {#S15}

Patients undergoing elective bariatric weight-loss surgery for were recruited for the ABOS study at Lille Regional University Hospital. Genotyping was carried out using the Illumina Human 1M-duo array, and data from 141 adults passed quality control. All participants gave written informed consent, and the study protocol was approved by the local ethics committee.

### Swedish discordant sibling cohort {#S16}

The SOS Sib Pair Study cohort was as previously published[@R21]. It includes 154 nuclear families, each with BMI discordant sibling pairs (BMI difference \>10 kg.m^−2^), giving a total of 732 subjects. Genotyping data using the Illumina 610K-Quad array was available for 353 siblings from 149 families. Expression data from subcutaneous adipose tissue (sampled after overnight fasting) were available for 360 siblings from 151 families. Subjects received written and oral information before giving written informed consent. The Regional Ethics Committee in Gothenburg approved the studies.

Statistical Methods {#S17}
===================

In view of the low frequency of the 16p11.2 deletions, all reported statistical tests were carried out using Fisher's exact test[@R29]. This was applied to comparisons of separately-ascertained cohorts or categories and was carried out on contingency tables constructed for the number of subjects carrying/lacking a 16p11.2 deletion (zero or one copies, as no homozygous deletions were observed) versus the obesity status/ascertainment of the individual. Since no homozygous deletions were observed, it was unnecessary to make a prior distinction between recessive, additive and dominant models of disease risk. For overall analysis of the obesity risk resulting from a deletion, cohorts were pooled according to their obesity status determined according to the criteria described above, and the described tests were then applied to the pooled data. Odds ratios and 95% confidence limits were calculated as described[@R30].

CNV discovery and validation {#S18}
----------------------------

### Clinical identification of 16p11.2 deletions {#S19}

All diagnostic procedures (aCGH, qPCR, QMPSF, FISH) were carried out according to the relevant guidelines of good clinical laboratory practice for the respective countries. All rearrangements in probands were confirmed by a second technique and karyotyping was performed in all cases to exclude a complex rearrangement.

### cnvHap {#S20}

CNVs were detected in the child/adult case-control, bariatric surgery, SOS sibpair and NFBC cohorts using the cnvHap algorithm (Coin *et al*., manuscript submitted); this method is based on an Hidden Markov Model which models transitions between copy number states at the haplotype level, improving sensitivity and accuracy by capturing LD information between CNVs and SNPs. The compiled JAR and associated parameter files can be downloaded from <http://www.imperial.ac.uk/medicine/people/l.coin/>. Sample data from the algorithm applied to the NFBC cohort is illustrated in [Supplementary Figure S5a](#SD2){ref-type="supplementary-material"}.

After clustering of genotyping data using the internal Illumina BeadStudio cluster files, values for logR ratio (LRR) and B allele frequency (BAF) were exported from each project and normalised: Effects of %GC content on LRR were removed by regressing on GC and GC[@R2], while wave effects[@R31] were removed by fitting a loess function. Normalised data for probes within 2.5Mb of the 16p11.2 deletion were analysed using cnvHap, and CNV calls intersecting the single-copy sequences within the deletion (chr16:29514353-30107356, build hg18) were extracted. 16p11.2 deletions were identified by a minimum 90% of probes within the deleted region being called as having reduced copy number.

All called 16p11.2 deletions were validated by direct analysis of LRR. Data for each probe were normalised by first subtracting the median value across all samples (so that the distribution of LRR for each probes was centred on zero), and then dividing by the variance across all samples (to correct for variation in the sensitivity of different probes to copy number variation). The normalised data were then smoothed by application of a 9-point moving average and visualised graphically (see [Supplementary Figure S6](#SD2){ref-type="supplementary-material"}); putative deletions were checked by subsequent manual confirmation of loss-of-heterozygosity across the entire region. Equally, all deletions called by this method were confirmed by cnvHap.

### Gaussian Mixture Model {#S21}

For the CoLaus cohort, raw genotyping data were normalized using the aroma.affymetrix framework[@R32]. Normalization steps included allelic cross-talk calibration[@R33],[@R34], intensity summarization using robust median average and correction for any PCR amplification bias. CN ratios for a given sample, at a given SNP or CN probe, were computed as the log~2~ ratio of the normalized intensity of this probe divided by the median across all the samples. CN ratios were subsequently smoothed by fitting a Loess function[@R31]. CNV calling was done using a new method based on a Gaussian mixture model (Valsesia *et al*., manuscript in preparation). This Gaussian mixture model fits four components (deletion, copy neutral, 1 and 2 additional copy) to CN ratios. The final copy number at each probe location is determined as the expected (dosage) copy number. The method has been validated by comparing test datasets with results from the CNAT[@R35] and CBS[@R36],[@R37] algorithms and by replicating a subset of CoLaus subject on Illumina arrays. All calls at the 16p11.2 locus made by the highly stringent CBS algorithm were replicated by the Gaussian mixture model. Principal components analysis detected no significant batch effects. Sample data from the algorithm applied to the CoLaus cohort is illustrated in [Supplementary Figure S5b](#SD2){ref-type="supplementary-material"}.

### PennCNV, QuantiSNP and Birdsuite {#S22}

CNV discovery in the EGPUT cohort was carried out using QuantiSNP[@R38], PennCNV[@R39] and BeadStudio GT module (Illumina Inc.). All analyses were carried out using the recommended settings, except changing EMiters to 25 and L to 1,000,000 in QuantiSNP. For PennCNV, the Estonian population-specific B-allele frequency file was used. Data from the SCOOP cohort were analysed using Affymetrix Power Tools and Birdsuite software[@R40]

### Multiplex ligation-dependent probe amplification (MLPA) {#S23}

MLPA was carried out according to standard methods[@R41] using reagents obtained from MRC-Holland (Amsterdam NL). The SALSA MLPA Kit P343-B1 Autism-1 probemix was used, which contained 9 probes within the deleted region on 16p11.2, plus one probe upstream and one downstream of this locus (see [Figure 1a](#F1){ref-type="fig"}). MLPA products were separated using an AB3130 Genetic Analyser (Applied Biosystems) and outputs were analysed using GeneMarker software (Soft Genetics) and Microsoft Excel. Data normalisation was carried out by dividing the peak areas for each of the 11 test probes by the mean of 9 control probe peak areas. Normalised peak area data were then compared across the tested samples to determine which ones carried the 16p11.2 deletion.

Supplementary Material {#SM}
======================
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![Identification and validation of deletions at 16p11.2\
(**a**) aCGH data showing the location of the 16p11.2 deletion. The data show the log~2~ intensity ratio for a deletion carrier compared to an undeleted control sample. Grey bars connected by a broken line denote the segmental duplication flanking the deletion region. Vertical bars indicate the positions of the probe pairs used for MLPA validation. Note that CGH and genotyping array probes targeted against segmental duplications may not accurately report copy number due to the increased number of homologous sequences in the diploid state. Genome coordinates are according to the hg18 build of the reference genome. (**b**) MLPA validation of 16p11.2 deletions. Representative MLPA results are shown, illustrating one instance of maternal transmission and two instances of *de novo* deletions. Genotyping data excluded the possibility of non-paternity. Full results for MLPA validation and inheritance analysis are shown in [Supplementary Figure S1](#SD2){ref-type="supplementary-material"}. Each panel shows the relative magnitude of the normalised, integrated signal at each probe location, in order of chromosomal position of the MLPA probe pairs as indicated in (a). Each panel corresponds to its respective position on the associated pedigree, as shown.](ukmss-28221-f0001){#F1}

![Dependence of BMI on age in subjects having a deletion at 16p11.2\
Data are for all individuals carrying a deletion for whom phenotypic data are available. Similar data from this study only are shown in Supplementary Figures [S2](#SD2){ref-type="supplementary-material"} and [S3](#SD2){ref-type="supplementary-material"}. Lines denote the age- and gender-corrected thresholds (solid/broken -- male/female) for obesity and morbid obesity. Symbols are: Square/circle -- male/female; black/grey -- ascertained/not ascertained for developmental delay; filled/open -- ascertained/not ascertained for obesity; diamond -- first-degree relative of proband; cross -- previously published data[@R10]-[@R15]. The 31 year old male with BMI \~20 kg.m^−2^ was diabetic based on fasting blood glucose \>7 mmol/L.](ukmss-28221-f0002){#F2}

###### Frequency of detected 16p11.2 deletions in multiple cohorts

For each cohort, 16p11.2 deletions were identified and validated using the indicated technologies. Where full phenotypic data was available, members of cohorts were categorised according to the appropriate obesity criteria (see [Supplementary Information](#SD2){ref-type="supplementary-material"})

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cohort                                                                                                       Deletions/Total   Technology                                    
  ------------------------------------------------------------------------------------------------------------ ----------------- ------------ ---------- ----------- --------- ---------------------------
  Ascertained for cognitive deficits/malformations and obesity                                                                                                                 

    Lille/Strasbourg[a](#TFN1){ref-type="table-fn"}                                                                                                                  8/279     qPCR, aCGH

    London[a](#TFN1){ref-type="table-fn"}                                                                                                                            1/33      aCGH, MLPA

  *Ascertained for cognitive deficits/malformations*                                                                                                                           

    French-Swiss cytogenetic clinical diagnostic group[a](#TFN1){ref-type="table-fn"}                                                                                21/3870   aCGH, QMPSF, qPCR, FISH

    Estonian cases of cognitive deficit[a](#TFN1){ref-type="table-fn"}                                                                                               1/77      Illumina CNV370-Duo, qPCR

  *Ascertained for obesity*                                                                                                                                                    

    Swedish families with discordant siblings[b](#TFN2){ref-type="table-fn"},[d](#TFN4){ref-type="table-fn"}   0/140             0/54         0/115      2/44        2/353     Illumina 610K-Quad, MLPA

    French adult case-control[b](#TFN2){ref-type="table-fn"}                                                   0/669             0/174        \-         4/705       4/1548    Illumina CNV370-Duo, MLPA

    French child case-control[c](#TFN3){ref-type="table-fn"}                                                   0/530             0/51         1/260      3/383       4/1224    Illumina CNV370-Duo, MLPA

    British extreme early-onset obesity (SCOOP)[c](#TFN3){ref-type="table-fn"}                                                                           3/931       3/931     Affymetrix 6.0, MLPA

    French bariatric weight-loss surgery[b](#TFN2){ref-type="table-fn"}                                        \-                \-           0/15       2/126       2/141     Illumina 1M-duo, MLPA

  *Population cohorts (origin)*                                                                                                                                                

    NFBC66 (Finnish)[b](#TFN2){ref-type="table-fn"}                                                            1/3148            0/1622       1/434      1/42        3/5246    Illumina CNV370-Duo

    CoLaus (Swiss)[b](#TFN2){ref-type="table-fn"}                                                              0/2675            0/2049       0/830      0/58        0/5612    Affymetrix 500K

    EGPUT (Estonian)[b](#TFN2){ref-type="table-fn"}                                                            0/412             0/358        1/213      0/15        1/998     Illumina CNV370-Duo, qPCR

  Total without ascertainment for cognitive\                                                                   *1/7434*          *0/4254*     *3/1742*   *13/2260*             
  deficits/malformations[d](#TFN4){ref-type="table-fn"}                                                                                                                        
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Not categorised, complete phenotypic data not available.

BMI thresholds for overweight, obese, morbidly obese were ≥25 kg.m^−2^, ≥30 kg.m^−2^, ≥40 kg.m^−2^ respectively.

BMI thresholds for overweight, obese, morbidly obese were the age- and gender-corrected 90^th^ precentile, 97^th^ precentile, +4 standard deviations above the mean, respectively.

Discordant siblings not included in totals due to relatedness.
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